Adis Drug Clinical Q&A

Drugs & Therapy Perspectives

, Volume 28, Issue 11, pp 1-5

First online:

Bilastine: a guide to its use in the treatment of symptomatic allergic rhinoconjunctivitis and urticaria

  • Katherine A. Lyseng-WilliamsonAffiliated withAdis Email author 
  • , Natalie J. CarterAffiliated withAdis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Bilastine, a new antihistamine, is indicated for the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria in many European countries. In clinical trials, the efficacy of bilastine in these indications was similar to that of other second-generation antihistamines. Bilastine is well tolerated, with an overall tolerability profile similar to that of placebo.